Otsuka Pharmaceutical Co., Ltd. Sustainability Profile
Otsuka Pharmaceutical Co., Ltd., a leading global healthcare company headquartered in Japan, has established itself as a key player in the pharmaceutical and nutraceutical industries. Founded in 1964, Otsuka has made significant strides in developing innovative products that address unmet medical needs, particularly in areas such as mental health, oncology, and cardiovascular health. With a strong presence in regions including North America, Europe, and Asia, Otsuka is renowned for its unique offerings, such as the antipsychotic medication Abilify and the hydration solution Pocari Sweat. The company’s commitment to research and development has led to numerous breakthroughs, solidifying its market position and earning recognition for its contributions to global health. Otsuka continues to focus on advancing science and improving patient outcomes through its diverse portfolio of pharmaceuticals and nutraceuticals.
DitchCarbon Score
How does Otsuka Pharmaceutical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Otsuka Pharmaceutical Co., Ltd.'s score of 60 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Otsuka Pharmaceutical Co., Ltd., headquartered in Japan, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas (GHG) emissions. The company has pledged to reduce absolute Scope 1 and Scope 2 GHG emissions by 30% by 2030, using 2017 as the baseline year. Additionally, Otsuka aims to cut its absolute Scope 3 emissions by 20% within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Otsuka's commitment to contributing to global efforts to limit temperature rise to 2°C. The reduction targets encompass emissions from the company's direct operations (Scope 1), indirect emissions from purchased energy (Scope 2), and other indirect emissions across its value chain (Scope 3). As of now, there is no specific emissions data available for Otsuka Pharmaceutical Co., Ltd. However, the company's proactive stance on climate action is evident through its established reduction targets, which are cascaded from its parent organization, Otsuka Holdings Co., Ltd. This corporate family relationship underscores Otsuka's commitment to sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 101,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 159,000,000 | - | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 866,000,000 | - | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Otsuka Pharmaceutical Co., Ltd.'s Industry?
How Carbon Intensive is Otsuka Pharmaceutical Co., Ltd.'s Location?
Otsuka Pharmaceutical Co., Ltd.'s Scope 3 Categories Breakdown
Otsuka Pharmaceutical Co., Ltd.'s Scope 3 emissions, which increased by 0% last year and increased by approximately 15% since 2016, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 67% of Scope 3 emissions.
Top Scope 3 Categories
Otsuka Pharmaceutical Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Otsuka Pharmaceutical Co., Ltd. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
